Protedyne said this week that it has appointed Fran Tuttle as president and CEO. Tuttle will also join the company's board of directors.
Most recently, Tuttle was senior vice president of near patient testing at Bayer Diagnostics. Prior to that, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics). Tuttle began her career as a CPA at Peat, Marwick, Mitchell, and Company (now KPMG). She holds an MBA from Harvard Business School.
Protedyne also said that Rolf Classon has been elected chairman of the board. Classon has served on Protedyne's board of directors since August 2004.
Trevor Hawkins stepped down this week as president and CEO of MDS to take a position in Europe with Phillips. Hawkins has also resigned from the board of Tm Bioscience.
Prior to MDS, Hawkins served as president of the molecular diagnostics business unit at GE Healthcare. Previously, he was senior vice president of development and new business initiatives at Amersham Biosciences and director of the Human Genome Project at the US Department of Energy's Joint Genome Institute.
Janet Lankard has been named vice president of sales and technology collaborations at VisEn Medical, the imaging company said last week.
Lankard joins VisEn from Quantum Dot, where she served as vice president of sales and technical support. She also worked at Affymetrix from 1998 to 2004, where she worked first as a regional sales manager and later as director of sales and technical support for North America west. Before joining Affy, Lankard was an executive sales account manager at Applied Biosystems from 1991 to 1998.
Lankard holds a BSc in biochemistry from California Polytechnic University, San Luis Obispo.
Definiens this week released Cellenger, automated multivariate image analysis software for cell-based assays.
Cellenger is a set of workflow tools and modular image analysis components which, when combined with any of the Definiens Enterprise Client Applications, provides a complete system for working with cell-based assays, the company said. Cellenger uses an object-oriented, context-based, hierarchical network process to analyze images. The software supports all common plate and image formats, and is instrument and process independent, and thus provides users the power to combine image data from multiple platforms and multiple experiments from assay development through full screening, Definiens said.
Additional features of Cellenger include a development environment for expert users, a customizable connector builder for non-standard image acquisition devices, and integration with databases for import and export of images and image data, Definiens said. The worldwide shipping of Cellenger is planned to start in the second quarter of 2006.
Sigma-Aldrich, a member of the RNAi Consortium, this week introduced the MISSION TRC shRNA Human Tumor Suppressor Gene Family, the first in a series of shRNA target sets that allow for rapid RNAi cell-based screens in mammalian systems not easily manipulated by traditional siRNA, Sigma said. The lentiviral transduction particle format eliminates the need to propagate bacterial cells, purify plasmid DNA, or undertake the lengthy process of preparing virus. Lentiviral-based shRNA can be used to create a stable knockdown in almost any mammalian cell type, including primary and non-dividing cells, Sigma said.